Jeff Cohn
General Counsel and Corporate Secretary Connect Biopharma
Seminars
Wednesday 5th August 2026
Panel Discussion: Strengthening IPO Readiness to Reduce Liability Exposure & Support Defensible Board Decision‑Making
3:15 pm
- Build disclosure discipline early by aligning scientific claims, press releases, BD decks, and public statements to withstand S‑1 scrutiny
- Reduce litigation and enforcement risk through structured risk‑factor design and clear escalation controls
- Strengthen Board decision‑making with disciplined go/no‑go criteria, documentation standards, and scenario pathways
- Prepare for life as a public company by aligning IPO readiness with post‑IPO ongoing public company obligations, capital markets strategy, contingency planning, and dual‑track financing scenarios
